Mereo BioPharma Group plc - ADR
$0.25
$-0.02
(-8.16%)
As on 04-Sep-2026 16:26EDT
Market cap
$43 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.2
-
Debt to Equity
0
-
Book Value
$0.2
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
159,690,973
9 Years Aggregate
CFO
$-228.85 Mln
EBITDA
$-279.13 Mln
Net Profit
$-360.82 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mereo BioPharma Group - ADR
| -40.0 | -20.8 | -25.2 | -85.5 | -44.2 | -38.1 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Mereo BioPharma Group - ADR
| -88.1 | 51.0 | 208.0 | -53.1 | -55.3 | 9.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mereo BioPharma Group - ADR
|
0.3 | 42.7 | 0.0 | -28.1 | -- | -80.7 | -- | 1.5 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Mereo BioPharma Group - ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of... osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom. Read more
-
Co-Founder, CEO & Executive Director
Dr. Denise Vera Scots-Knight Ph.D.
-
Co-Founder, CEO & Executive Director
Dr. Denise Vera Scots-Knight Ph.D.
-
Headquarters
London
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Mereo BioPharma Group - ADR
What is the current share price of Mereo BioPharma Group plc - ADR Today?
The share price of Mereo BioPharma Group plc - ADR is $0.25 (NASDAQ) as of 04-Sep-2026 16:26 EDT. Mereo BioPharma Group plc - ADR has given a return of -44.21% in the last 3 years.
What is the current PB & PE ratio of Mereo BioPharma Group plc - ADR?
Since, TTM earnings of Mereo BioPharma Group plc - ADR is negative, P/E ratio is not available.
The P/B ratio of Mereo BioPharma Group plc - ADR is 1.49 times as on 04-Sep-2026, a 71 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.32 |
0.32 |
2024 |
-12.55 |
8.91 |
2023 |
-10.85 |
6.32 |
2022 |
-2.21 |
1.82 |
2021 |
10.88 |
1.57 |
What is the 52 Week High and Low of Mereo BioPharma Group plc - ADR?
The 52-week high and low of Mereo BioPharma Group plc - ADR are Rs 2.37 and Rs 0.20 as of 06-Sep-2026.
What is the market cap of Mereo BioPharma Group plc - ADR?
Mereo BioPharma Group plc - ADR has a market capitalisation of $ 43 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Mereo BioPharma Group plc - ADR?
Before investing in Mereo BioPharma Group plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.